FDA approves IntelGenx’s Rizafilm for acute migraine treatment
Pharmaceutical Technology
APRIL 18, 2023
IntelGenx Corp announced that the US Food and Drug Administration (FDA) has approved the company’s Rizafilm VersaFilm new drug application (NDA) for the treatment of acute migraine. Rizaport and Maxalt are different formulations of Rizatriptan benzoate.
Let's personalize your content